SCHEMBL23699080

SCHEMBL23699080

COc1ccc(NC(=O)C(C)N2CC3C(C2)C3Nc2ccnc3ccc(F)cc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 18/20 0.50
CYP2C9 P11712 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C8 P10632 1/20 0.44
TDO2 P48775 1/20 0.44
KCNH2 Q12809 1/20 0.44
PDGFRA P16234 2/20 0.42
KDR P35968 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30444329 0.92 IDO1 (0.45) IDO1
SCHEMBL23707441 0.92 IDO1 (0.45) IDO1
SCHEMBL23707447 0.90 IDO1 (0.55) IDO1CYP2C9CYP3A4CYP2C8TDO2
SCHEMBL23699096 0.90 IDO1 (0.49) IDO1CYP2C9CYP3A4CYP2C8TDO2
SCHEMBL23699153 0.83 IDO1 (0.48) IDO1CYP2C9
SCHEMBL23699147 0.81 IDO1 (0.43) IDO1CYP3A4
SCHEMBL23699077 0.78 IDO1 (0.53) IDO1CYP2C9CYP3A4CYP2C8TDO2
SCHEMBL23699160 0.78 IDO1 (0.53) IDO1CYP2C9CYP3A4CYP2C8TDO2
SCHEMBL30444764 0.78 IDO1 (0.53) IDO1CYP2C9CYP3A4CYP2C8TDO2
SCHEMBL23699116 0.78 IDO1 (0.44) IDO1CYP2C9CYP3A4CYP2C8TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110950842-B Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity 深圳微芯生物科技股份有限公司 2023-06-20 CN claimed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US claimed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP claimed
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2026-02-17 US disclosed
CN-116574105-A Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity 深圳微芯生物科技股份有限公司 2023-08-11 CN disclosed
CN-110950842-B Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity 深圳微芯生物科技股份有限公司 2023-06-20 CN disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity IDO2, IDO1, HDAC2 IDO1 2/4885CYP2C9 715/4885CYP3A4 1276/4885
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY IDO1, IDO2, INMT IDO1 1/4885CYP2C9 1821/4885CYP3A4 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.